Current and Promising Histone Deacetylase Inhibitors in Cancer Therapy

<p><strong><span>Abstract:</span></strong><span> Cancer is the most critical disease distressing humans and a primary cause of death on a global scale. Lately, the use of targeted anticancer medications as an approach for optimizing antitumor therapy has been urged. Changes in epigenetics in eukaryotic biological processes can result in the up- or downregulation of regulatory proteins contributing to disease onset and progression. Histone deacetylases (HDACs) have been one of the most researched epigenetic targets over the past three decades, also, HDAC enzymes are promising drug targets for the treatment of cancer. Truly, abnormal HDAC expression is associated with various kinds of cancer and neuro-degenerative disorders, establishing HDACs promising molecular targets for the design of new drugs. Numerous HDAC inhibitors (HDACIs) are currently in clinical evaluation for different forms of cancer, and some of them have reached the market following food and drug administration (FDA) approval. This review summarizes the various HDAC classes and discuss different classes HDACIs with a dedicated focus on late-stage preclinical candidates and drugs in clinical trials. Lastly, but just as importantly, we shed light on the future directions in HDACIs design which may help researchers in development and discovery of new horizons in cancer treatment.</span></p> <p><strong><span>Keywords:</span></strong><span> Cancer, Clinical trials, Histone deacetylases, HDAC inhibitors.</span></p> <p><strong><span>Title:</span></strong><span> Current and Promising Histone Deacetylase Inhibitors in Cancer Therapy</span></p> <p><strong><span>Author: </span></strong><span>Heba A. Hofny, Mamdouh F.A. Mohamed, El-Shimaa M. N. Abdelhafez, Heba A. Hassan, Gamal El-Din A. Abuo-Rahma</span></p> <p><strong><span>International Journal of Novel Research in Physics Chemistry & Mathematics</span></strong></p> <p><strong><span>ISSN 2394-9651</span></strong></p> <p><strong><span>Vol. 12, Issue 1, January 2025 - April 2025</span></strong></p> <p><strong><span>Page No: 35-52</span></strong></p> <p><strong><span>Novelty Journals</span></strong></p> <p><strong><span>Website: www.noveltyjournals.com</span></strong></p> <p><strong><span>Published Date: 03-</span></strong><strong><span>March</span><span>-2025</span></strong></p> <p><strong><span>DOI: </span></strong><span><a href="https://doi.org/10.5281/zenodo.14959413"><strong><span>https://doi.org/10.5281/zenodo.14959413</span></strong></a></span></p> <p><strong><span>Paper Download Link (Source)</span></strong></p> <p><strong><span><a href="https://www.noveltyjournals.com/upload/paper/Current%20and%20Promising%20Histone-03032025-2.pdf">https://www.noveltyjournals.com/upload/paper/Current%20and%20Promising%20Histone-03032025-2.pdf</a></span></strong></p>

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-03-03
DOI
https://doi.org/10.5281/zenodo.14959413
Primary Topic
Histone Deacetylase Inhibitors Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Current and Promising Histone Deacetylase Inhibitors in Cancer Therapy

Zenodo (CERN European Organization for Nuclear Research)
Histone Deacetylase Inhibitors Research
article

Current and Promising Histone Deacetylase Inhibitors in Cancer Therapy

article en

Abstract

<p><strong><span>Abstract:</span></strong><span> Cancer is the most critical disease distressing humans and a primary cause of death on a global scale. Lately, the use of targeted anticancer medications as an approach for optimizing antitumor therapy has been urged. Changes in epigenetics in eukaryotic biological processes can result in the up- or downregulation of regulatory proteins contributing to disease onset and progression. Histone deacetylases (HDACs) have been one of the most researched epigenetic targets over the past three decades, also, HDAC enzymes are promising drug targets for the treatment of cancer. Truly, abnormal HDAC expression is associated with various kinds of cancer and neuro-degenerative disorders, establishing HDACs promising molecular targets for the design of new drugs. Numerous HDAC inhibitors (HDACIs) are currently in clinical evaluation for different forms of cancer, and some of them have reached the market following food and drug administration (FDA) approval. This review summarizes the various HDAC classes and discuss different classes HDACIs with a dedicated focus on late-stage preclinical candidates and drugs in clinical trials. Lastly, but just as importantly, we shed light on the future directions in HDACIs design which may help researchers in development and discovery of new horizons in cancer treatment.</span></p> <p><strong><span>Keywords:</span></strong><span> Cancer, Clinical trials, Histone deacetylases, HDAC inhibitors.</span></p> <p><strong><span>Title:</span></strong><span> Current and Promising Histone Deacetylase Inhibitors in Cancer Therapy</span></p> <p><strong><span>Author: </span></strong><span>Heba A. Hofny, Mamdouh F.A. Mohamed, El-Shimaa M. N. Abdelhafez, Heba A. Hassan, Gamal El-Din A. Abuo-Rahma</span></p> <p><strong><span>International Journal of Novel Research in Physics Chemistry & Mathematics</span></strong></p> <p><strong><span>ISSN 2394-9651</span></strong></p> <p><strong><span>Vol. 12, Issue 1, January 2025 - April 2025</span></strong></p> <p><strong><span>Page No: 35-52</span></strong></p> <p><strong><span>Novelty Journals</span></strong></p> <p><strong><span>Website: www.noveltyjournals.com</span></strong></p> <p><strong><span>Published Date: 03-</span></strong><strong><span>March</span><span>-2025</span></strong></p> <p><strong><span>DOI: </span></strong><span><a href="https://doi.org/10.5281/zenodo.14959413"><strong><span>https://doi.org/10.5281/zenodo.14959413</span></strong></a></span></p> <p><strong><span>Paper Download Link (Source)</span></strong></p> <p><strong><span><a href="https://www.noveltyjournals.com/upload/paper/Current%20and%20Promising%20Histone-03032025-2.pdf">https://www.noveltyjournals.com/upload/paper/Current%20and%20Promising%20Histone-03032025-2.pdf</a></span></strong></p>

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Openalex Percentile: Top 53%
Histone Deacetylase Inhibitors Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.